Evidence map›Paper›PMID 34950005›Full record

ArticleCase reports in oncology

Different Therapeutic Strategies in 2 Young Patients with Advanced ALK-Rearranged Lung Adenocarcinoma: "The Light at the End of the Tunnel".

Umberto Caterino, Cristiano Cesaro, Enzo Zamparelli, Flavio Cesaro, Alba Palma, Raffaella Lucci, Pasquale Imitazione, Dino Casazza, Dario Amore

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 76% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Umberto CaterinoUnit of Bronchology, Monaldi Hospital - A.O. dei Colli Naples, Naples, Italy.
Cristiano CesaroUnit of Bronchology, Monaldi Hospital - A.O. dei Colli Naples, Naples, Italy.
Enzo ZamparelliUnit of Anesthesia and Resuscitation, Monaldi Hospital - A.O. dei Colli of Naples, Naples, Italy.
Flavio CesaroUnit of Emergency Medicine and Surgery and First Aid, C.T.O. Hospital, Torino, Italy.
Alba PalmaUnit of Emergency Medicine and Surgery and First Aid, C.T.O. Hospital, Torino, Italy.
Raffaella LucciUnit of Pathological Anatomy, Monaldi Hospital - A.O. dei Colli of Naples, Naples, Italy.
Pasquale ImitazioneDepartment of Respiratory Pathophysiology and Rehabilitation, Monaldi Hospital - A.O. dei Colli of Naples, Naples, Italy.
Dino CasazzaUnit of Thoracic Surgery, Monaldi Hospital - A.O. dei Colli Naples, Naples, Italy.
Dario AmoreUnit of Thoracic Surgery, Monaldi Hospital - A.O. dei Colli Naples, Naples, Italy.
Ospedale Monaldi · ITCTO Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant pleural effusion represents a prognostic negative factor on survival conferring stage IV disease. The median of survival is 5 months and a 5-year survival of about 3%. We describe the therapeutic success obtained from different strategies in anaplastic lymphoma kinase (ALK) inhibitors in 2 young women showing malignant pleural effusion secondary to advanced ALK-rearranged lung adenocarcinoma. This report shows that for patients with EGFR mutations in advanced lung adenocarcinoma-associated malignant pleural effusion, complete response to EGFR TKI inhibitor can be observed mostly if pleural effusion and primary lung adenocarcinoma show the same EGFR mutation status.

Indexed as

Anaplastic lymphoma kinase inhibitor therapyLung adenocarcinomaMalignant pleural effusion

Identifiers

PMID34950005
PMCPMC8647055
OpenAlexW3212698720

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.